Austria-based payment brand Bluecode has announced the launch...

Boxo has partnered with global payments infrastructure firm

Nepal Clearing House Limited (NCHL) and

Everest Bank has...

Emirates NBD and...

US-based fintech Felix Pago has announced a partnership...

Lithuania-based iDenfy has introduced an AI-powered Data Crossmatch feature aimed at improving the Know Your Business (KYB) compliance process.

Singapore-based TransferTo has partnered with the Pan-African Ecobank Group in order to expand financial access and cross-border payments across the region of Africa.

Mbank has partnered with Al Etihad Payments Company (AEP), a Central Bank of the UAE (CBUAE) subsidiary, to introduce the Aani Instant Payment Platform on its mobile application.

A friend is investigating the use of generative AI in his classes. I asked two different popular chatbots to write MATLAB programs for a mathematically nontrivial problem. Both chatbots understood my query and both wrote plausible MATLAB programs, but one of the programs was not correct. My recommendation for coursework: carefully read and test programs produced by generative AI and repair any incorrect ones.... read more >>

Source: Streetwise Reports 11/07/2024

Dakota Gold Corp. (DC:NYSE American) announced drill results from the first 17 holes of its ongoing infill drilling program to expand the maiden resource at its Richmond Hill Gold Project in the historic Homestake District of South Dakota.

An updated S-K 1300 resource estimate is planned for Q1 2025 and a S-K 1300 Initial Assessment with cashflow analysis is planned for Q2 2025, the company said in a release. The expanded resource is expected to include an additional 88 new drill holes totaling 17,000 meters.

"The highlight of this morning's release was (hole) RH24C-099, which was drilled in the Twin Tunnels Zone and returned 1.15 g/t Au (grams per tonne gold) over 51.7 meters from 132.9 meters," wrote Canaccord Genuity Capital Markets Analyst Peter Bell in an updated research note on Monday. "The results this morning were consistent with the current resource at Richmond Hill, with many cases reporting higher-than-average grades."

Bell said the firm was encouraged by the results, "which we believe provide support for expansion in future resource estimates. With infill and step out drilling at Richmond Hill being just one of three ongoing drill programs currently underway at Dakota, underscoring the company's emphasis on exploration and expansion."

Drilling Is 'Adding Ounces'

The maiden S-K 1300 resource, announced in April, outlined an Indicated Resource of 51.83 million tonnes (Mt) at 0.80 g/t Au for 1.33 million ounces (Moz) and Inferred Resource of 58.06 Mt at 0.61 g/t Au for 1.13 Moz., the company said.

The initial infill drill results release released Monday encountered further gold mineralization from the central portion of the Richmond Hill resource area consistent with results reported in the maiden resource, Dakota said. The drilling was conducted in areas where the original resource block model contained gaps to support the company's belief that the initial resource could be significantly expanded with additional infill drilling.

Highlights of the results include:

• Hole RH24C-077: 0.76 g/t Au over 24.4 meters
• Hole RH24C-083: 0.70 g/t Au over 13.8 meters
• Hole RH24C-085: 1.10 g/t Au over 17.9 meters
• Hole RH24C-088A: 0.96 g/t Au over 41.5 meters
• Hole RH24C-099: 1.15 g/t Au over 51.7 meters

Dakota said the resource remained open in all directions and could be improved with more drilling, metallurgical work, and incorporation of silver into the resource.

"We are very pleased to see that initial results from our infill drill program are adding ounces to our current S-K 1300 resource," said Dakota Vice President of Exploration James Berry. "The results to date show grades and widths consistent with drill holes in the original block model and support an expansion of gold mineralization, including shallow oxide mineralization. We look forward to continuing our infill program on the other zones identified in our Initial assessment for follow-up drilling."

'Vastly Unexplored' District

The historic Homestake Mine produced 41 Moz Au and 9 Moz silver (Ag) over 126 years. The company has 48,000 acres of holdings surrounding the original mine, which was first discovered in 1876 and consolidated by George Hearst.

Areas surrounding "super-giant deposits" like Homestake are believed to contain significant additional gold resources, wrote John Newell wrote.

Areas surrounding "super-giant deposits" like Homestake are believed to contain significant additional gold resources, wrote John Newell of John Newell & Associates this week for a Streetwise Reports piece on the legacy of the famous mine.

"Super-giant deposits are characterized by clusters of geologically similar deposits within several hundred square kilometers, defining profoundly mineralized regions," Newell wrote. "It is believed that at least twice that amount of gold exists in the neighborhood of these super giants. If that is true, then there are at least 100 Moz of gold left to be found in this vastly underexplored precious metal district of South Dakota."

This proximity to a super-giant "suggests a high potential for similar deposits," Newell wrote. "Being in the shadow of many old mines increases the probability of finding significant mineral resources."

The Catalyst: Gold Continues Bull Market

After hitting a record high of US$2,790.15 per ounce on Thursday, spot gold was up 0.1% to US$2,737.35 on Monday afternoon, according to Reuters.

Investors were keeping a close on Tuesday's presidential election in the U.S. and the Federal Reserve's meeting later this week, Anjana Anil reported.

"A Reuters/Ipsos poll conducted last month found worries that the U.S. could see a repeat of the unrest that followed Trump's 2020 election defeat, when his false claim that his loss was the result of fraud prompted hundreds to storm the U.S. Capitol," Anil wrote.

Gold's rise has "resulted in big returns for the investors who bought in earlier this year," Angelica Leicht reported for CBS News last month. "For example, the investors who purchased gold in March when it hit US$2,160 per ounce have seen their gold values increase by nearly 27% in the time since. That's a huge uptick in value in a matter of months, especially on an asset that's known more for long-term growth."

Recently polled London Bullion Market Association members indicated they believe the gold price could reach US$2,940/oz during 2025, reported Stockhead on Oct. 28.

"Combined with expectations of lower global interest rates, this further enhances gold's attractiveness as an investment," the article noted.[OWNERSHIP_CHART-7442]

As for gold equities, the S&P/TSX Venture Composite Index (SPCDNX) confirmed a multidecade bull run for junior, intermediate, and senior mining stocks when it closed above 1,000 recently, Stewart Thomson with 321Gold wrote. The index is a key indicator of the health of the general gold, silver, and mining stocks market.

Ownership and Share Structure

According to the company, approximately 25% of its shares are with management and insiders.

Out of management, Co-chairman, Director, President and Chief Executive Officer Robert Quartermain holds the most shares at 8.4%, while COO Jerry Aberle holds 4.8%, the company said.

About 26% of the shares are with institutional investors, according to Yahoo Finance and Edgar filings. Top institutional holders include Fourth Sail Capital with 5.3%, Van Eck Associates with 4.1%, Blackrock Institutional Trust Co. with 3.7%, The Vanguard Group Inc. with about 3.2%, Fidelity Management and Research Co. LLC with 2.7%, and CI Global Asset Management with 2.6%.

About 16.5% is with strategic investors, including Orion Mine Finance, which owns about 9.9%, and Barrick Gold Corp., which owns about 2.5%. The rest is retail.

Dakota Gold has a market cap of US$212.61 million, with 93.66 million shares outstanding. It trades in a 52-week range of US$3.25 and US$1.84.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. Dakota Gold Corp. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$4,000 and US$5,000.
2. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Dakota Gold Corp.
3. Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
4. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

( Companies Mentioned: DC:NYSE American, )

Reconstructions from the Daynès Studio in Paris depict a male Neanderthal (right) face to face with a human, Homo sapiens.; Credit: /Science Source

It's something that many of us reckon with: the sense that we're not quite as sharp as we once were.

I recently turned 42. Having lost my grandfather to Alzheimer's, and with my mom suffering from a similar neurodegenerative disease, I'm very aware of what pathologies might lurk beneath my cranium.

In the absence of a cure for Alzheimer's and other forms of dementia, the most important interventions for upholding brain function are preventive — those that help maintain our most marvelous, mysterious organ.

Based on the science, I take fish oil and broil salmon. I exercise. I try to challenge my cortex to the unfamiliar.

As I wrote my recent book, A History of the Human Brain, which recounts the evolutionary tale of how our brain got here, I began to realize that so many of the same influences that shaped our brain evolution in the first place reflect the very measures we use to preserve our cognitive function today.

Being social, and highly communicative. Exploring creative pursuits. Eating a varied, omnivorous diet low in processed foods. Being physically active.

These traits and behaviors help retrace our past, and, I believe, were instrumental in why we remain on the planet today.

And they all were, at least in part, enabled by our brain.

Social smart alecks finish first

The human saga is riddled with extinctions.

By "human," I don't just mean Homo sapiens, the species we belong to, but any member of the genus Homo. We've gotten used to being the only human species on Earth, but in our not so distant past — probably a few hundred thousand years ago – there were at least nine of us running around.

There was Homo habilis, or the "handy man." And Homo erectus, the first "pitcher." The Denisovans roamed Asia, while the more well-known Neanderthals spread throughout Europe.

But with the exception of Homo sapiens, they're all gone. And there's a good chance it was our fault.

Humans were never the fastest lot on the African plains, and far from the strongest. Cheetahs, leopards and lions held those distinctions. In our lineage, natural selection instead favored wits and wiliness.

Plenty of us became cat food, but those with a slight cognitive edge — especially Homo sapiens — lived on. In our ilk, smarts overcame strength and speed in enabling survival.

Ecology, climate, location and just sheer luck would've played important roles in who persisted or perished as well, as they do for most living beings. But the evolutionary pressure for more complex mental abilities would lead to a massive expansion in our brain's size and neurocircuitry that is surely the paramount reason we dominate the planet like no other species ever has.

Much of this "success," if you can call it that, was due to our social lives.

Primates are communal creatures. Our close monkey and ape cousins are incredibly interactive, grooming each other for hours a day to maintain bonds and relationships. Throw in a few hoots and hollers and you have a pretty complex community of communicating simians.

An active social life is now a known preserver of brain function.

Research shows that social isolation worsens cognitive decline (not to mention mental health, as many of us experienced this past year). Larger social networks and regular social activities are associated with mental preservation and slowed dementia progression.

Entwined in this new social life was an evolutionary pressure that favored innovation. Our eventual ability to generate completely novel thoughts and ideas, and to share those ideas, came to define our genus.

As we hunted and foraged together, and honed stones into hand axes, there was a collective creativity at work that gave us better weapons and tools that enabled more effective food sourcing, and, later, butchering and fire. Effectively sharing these innovations with our peers allowed information to spread faster than ever before - a seed for the larger communities and civilizations to come.

Challenging ourselves to new pursuits and mastering new skills can not only impress peers and ingratiate us to our group, but literally help preserve our brain. New hobbies. New conversations. Learning the banjo. Even playing certain video games and simply driving a new route home from work each day, as neuroscientist David Eagleman does, can keep our function high.

Whether it's honing ancient stone or taking up Sudoku, any pursuit novel and mentally challenging may help keep the neural circuits firing.

We really are what we eat

All the while, as we hunted and crafted in new and communal ways, we had to eat. And we did so with an uniquely adventurous palette.

Homo sapiens is among the most omnivorous species on the planet. Within reason we eat just about anything. Whether it's leaves, meat, fungus, or fruit, we don't discriminate. At some point, one of us even thought it might be a good idea to try the glistening, grey blobs that are oysters - and shellfish are, it turns out, among the healthiest foods for our brain.

The varied human diet is an integral part of our story. As was the near constant physicality required to source it.

On multiple occasions over the past 1 to 2 million years climate changes dried out the African landscape, forcing our ancestors out of the lush forest onto the dangerous, wide-open grasslands. As evolution pressured us to create and commune to help us survive, a diverse diet also supported our eventual global takeover.

Our arboreal past left us forever craving the dangling fruits of the forest, a supreme source of high-calorie sugars that ensured survival. Back then we didn't live long enough to suffer from Type 2 diabetes: if you encountered sweets, you ate them. And today we're stuck with a taste for cookies and candy that, given our longer lifespans, can take its toll on the body and brain.

But humans were just as amenable to dining on the bulbs, rhizomes and tubers of the savanna, especially once fire came along. We eventually became adept scavengers of meat and marrow, the spoils left behind by the big cats, who preferred more nutritive organ meat.

As our whittling improved we developed spears, and learned to trap and hunt the beasts of the plains ourselves. There is also evidence that we learned to access shellfish beds along the African coast and incorporate brain-healthy seafood into our diet.

Studying the health effects of the modern diet is tricky. Dietary studies are notoriously dubious, and often involve countless lifestyle variables that are hard to untangle.

Take blueberries. Multiple studies have linked their consumption with improved brain health. But, presumably, the berry-prone among us are also more likely to eat healthy all around, exercise, and make it to level 5 on their meditation app.

Which is why so many researchers, nutritionists, and nutritional psychiatrists now focus on dietary patterns, like those akin to Mediterranean culinary customs, rather than specific ingredients. Adhering to a Mediterranean diet is linked with preserved cognition; and multiple randomized-controlled trials suggest doing so can lower depression risk.

A similar diversity in our ancestral diet helped early humans endure an ever-shifting climate and times of scarcity. We evolved to subsist and thrive on a wide range of foods, in part because our clever brains allowed us access to them. In turn, a similarly-varied diet (minus submitting to our innate sugar craving of course) is among the best strategies to maintain brain health.

All of our hunting, and foraging, and running away from predators would have required intense physical exertion. This was certainly not unique to humans, but we can't ignore the fact that regular exercise is another effective means of preserving brain health.

Being active improves performance on mental tasks, and may help us better form memories. Long before the Peletons sold out, our brains relied on both mental and physical activity.

But overwhelmingly the evidence points to embracing a collection of lifestyle factors to keep our brain healthy, none of which existed in a Darwinian vacuum.

Finding food was as social an endeavor as it was mental and physical. Our creative brains harnessed information; gossiping, innovating, and cooking our spoils around the campfire.

Researchers are beginning to piece together the complex pathology behind the inevitable decline of the human brain, and despite a parade of failed clinical trials in dementia, there should be promising treatments ahead.

Until then, in thinking about preserving the conscious experience of our world and relationships — and living our longest, happiest lives — look to our past.

Bret Stetka is a writer based in New York and an editorial director at Medscape. His work has appeared in Wired, Scientific American, and on The Atlantic.com. His new book, A History of the Human Brain, is out from Timber/Workman Press. He's also on Twitter: @BretStetka.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Chiquita Brooks-LaSure, administrator of the Centers for Medicare & Medicaid Services, leads some of the Biden administration's efforts to expand Medicaid access.; Credit: Caroline Brehman/CQ-Roll Call, Inc via Getty Imag

The Biden administration is quietly engineering a series of expansions to Medicaid that may bolster protections for millions of low-income Americans and bring more people into the program.

Biden's efforts — which have been largely overshadowed by other economic and health initiatives — represent an abrupt reversal of the Trump administration's moves to scale back the safety-net program.

The changes could further boost Medicaid enrollment — which the pandemic has already pushed to a record 80.5 million. Some of the expansion is funded by the COVID-19 relief bill that passed in March, including coverage for new mothers.

Others who could also gain coverage under Biden are inmates and undocumented immigrants. At the same time, the administration is opening the door to new Medicaid-funded services such as food and housing that the government insurance plan hasn't traditionally offered.

"There is a paradigm change underway," said Jennifer Langer Jacobs, Medicaid director in New Jersey, one of a growing number of states trying to expand home-based Medicaid services to keep enrollees out of nursing homes and other institutions.

"We've had discussions at the federal level in the last 90 days that are completely different from where we've ever been before," Langer Jacobs said.

Taken together, the Medicaid moves represent some of the most substantive shifts in federal health policy undertaken by the new administration.

"They are taking very bold action," said Rutgers University political scientist Frank Thompson, an expert on Medicaid history, noting in particular the administration's swift reversal of Trump policies. "There really isn't a precedent."

The Biden administration seems unlikely to achieve what remains the holy grail for Medicaid advocates: getting 12 holdout states, including Texas and Florida, to expand Medicaid coverage to low-income working-age adults through the Affordable Care Act.

And while some of the recent expansions – including for new mothers -- were funded by close to $20 billion in new Medicaid funding in the COVID relief bill Biden signed in March, much of that new money will stop in a few years unless Congress appropriates additional money.

The White House strategy has risks. Medicaid, which swelled after enactment of the 2010 health law, has expanded further during the economic downturn caused by the pandemic, pushing enrollment to a record 80.5 million, including those served by the related Children's Health Insurance Program. That's up from 70 million before the COVID crisis began.

The programs now cost taxpayers more than $600 billion a year. And although the federal government will cover most of the cost of the Biden-backed expansions, surging Medicaid spending is a growing burden on state budgets.

The costs of expansion are a frequent target of conservative critics, including Trump officials like Seema Verma, the former administrator of the Centers for Medicare & Medicaid Services, who frequently argued for enrollment restrictions and derided Medicaid as low-quality coverage.

But even less partisan experts warn that Medicaid, which was created to provide medical care to low-income Americans, can't make up for all the inadequacies in government housing, food and education programs.

"Focusing on the social drivers of health ... is critically important in improving the health and well-being of Medicaid beneficiaries. But that doesn't mean that Medicaid can or should be responsible for paying for all of those services," said Matt Salo, head of the National Association of Medicaid Directors, noting that the program's financing "is simply not capable of sustaining those investments."

Restoring federal support

However, after four years of Trump administration efforts to scale back coverage, Biden and his appointees appear intent on not only restoring federal support for Medicaid, but also boosting the program's reach.

"I think what we learned during the repeal-and-replace debate is just how much people in this country care about the Medicaid program and how it's a lifeline to millions," Biden's new Medicare and Medicaid administrator, Chiquita Brooks-LaSure, told KHN, calling the program a "backbone to our country."

The Biden administration has already withdrawn permission the Trump administration had granted Arkansas and New Hampshire to place work requirements on some Medicaid enrollees.

In April, Biden blocked a multibillion-dollar Trump administration initiative to prop up Texas hospitals that care for uninsured patients, a policy that many critics said effectively discouraged Texas from expanding Medicaid coverage through the Affordable Care Act, often called Obamacare. Texas has the highest uninsured rate in the nation.

The moves have drawn criticism from Republicans, some of whom accuse the new administration of trampling states' rights to run their Medicaid programs as they choose.

"Biden is reasserting a larger federal role and not deferring to states," said Josh Archambault, a senior fellow at the conservative Foundation for Government Accountability.

But Biden's early initiatives have been widely hailed by patient advocates, public health experts and state officials in many blue states.

"It's a breath of fresh air," said Kim Bimestefer, head of Colorado's Department of Health Care Policy and Financing.

Chuck Ingoglia, head of the National Council for Mental Wellbeing, said: "To be in an environment where people are talking about expanding health care access has made an enormous difference."

Mounting evidence shows that expanded Medicaid coverage improves enrollees' health, as surveys and mortality data in recent years have identified greater health improvements in states that expanded Medicaid through the 2010 health law versus states that did not.

Broadening eligibility

In addition to removing Medicaid restrictions imposed by Trump administration officials, the Biden administration has backed a series of expansions to broaden eligibility and add services enrollees can receive.

Biden supported a provision in the COVID relief bill that gives states the option to extend Medicaid to new mothers for up to a year after they give birth. Many experts say such coverage could help reduce the U.S. maternal mortality rate, which is far higher than rates in other wealthy nations.

Several states, including Illinois and New Jersey, had sought permission from the Trump administration for such expanded coverage, but their requests languished.

The COVID relief bill — which passed without Republican support — also provides additional Medicaid money to states to set up mobile crisis services for people facing mental health or substance use emergencies, further broadening Medicaid's reach.

And states will get billions more to expand so-called home and community-based services such as help with cooking, bathing and other basic activities that can prevent Medicaid enrollees from having to be admitted to expensive nursing homes or other institutions.

Perhaps the most far-reaching Medicaid expansions being considered by the Biden administration would push the government health plan into covering services not traditionally considered health care, such as housing.

This reflects an emerging consensus among health policy experts that investments in some non-medical services can ultimately save Medicaid money by keeping patients out of the hospital.

In recent years, Medicaid officials in red and blue states — including Arizona, California, Illinois, Maryland and Washington — have begun exploring ways to provide rental assistance to select Medicaid enrollees to prevent medical complications linked to homelessness.

The Trump administration took steps to support similar efforts, clearing Medicare Advantage health plans to offer some enrollees non-medical benefits such as food, housing aid and assistance with utilities.

But state officials across the country said the new administration has signaled more support for both expanding current home-based services and adding new ones.

That has made a big difference, said Kate McEvoy, who directs Connecticut's Medicaid program. "There was a lot of discussion in the Trump administration," she said, "but not the capital to do it."

Other states are looking to the new administration to back efforts to expand Medicaid to inmates with mental health conditions and drug addiction so they can connect more easily to treatment once released.

Kentucky health secretary Eric Friedlander said he is hopeful federal officials will sign off on his state's initiative.

Still other states, such as California, say they are getting a more receptive audience in Washington for proposals to expand coverage to immigrants who are in the country without authorization, a step public health experts say can help improve community health and slow the spread of communicable diseases.

"Covering all Californians is critical to our mission," said Jacey Cooper, director of California's Medicaid program, known as Medi-Cal. "We really feel like the new administration is helping us ensure that everyone has access."

The Trump administration moved to restrict even authorized immigrants' access to the health care safety net, including the "public charge" rule that allowed immigration authorities to deny green cards to applicants if they used public programs such as Medicaid. In March, Biden abandoned that rule.

KHN correspondent Julie Rovner contributed to this report.

KHN (Kaiser Health News) is a national newsroom that produces in-depth journalism about health issues. Together with Policy Analysis and Polling, KHN is one of the three major operating programs at KFF (Kaiser Family Foundation). KFF is an endowed nonprofit organization providing information on health issues to the nation.

This content is from Southern California Public Radio. View the original story at SCPR.org.

A COVID-19 vaccination clinic last month in Auburn, Maine. A drop in life expectancy in the U.S. stems largely from the coronavirus pandemic, a new study says.; Credit: Robert F. Bukaty/AP

A new study estimates that life expectancy in the U.S. decreased by nearly two years between 2018 and 2020, largely due to the COVID-19 pandemic. And the declines were most pronounced among minority groups, including Black and Hispanic people.

In 2018, average life expectancy in the U.S. was about 79 years (78.7). It declined to about 77 years (76.9) by the end of 2020, according to a new study published in the British Medical Journal.

"We have not seen a decrease like this since World War II. It's a horrific decrease in life expectancy," said Steven Woolf of the Virginia Commonwealth University School of Medicine and an author of the study released on Wednesday. (The study is based on data from the National Center for Health Statistics and includes simulated estimates for 2020.)

Beyond the more than 600,000 deaths in the U.S. directly from the coronavirus, other factors play into the decreased longevity, including "disruptions in health care, disruptions in chronic disease management, and behavioral health crisis, where people struggling with addiction disorders or depression might not have gotten the help that they needed," Woolf said.

The lack of access to care and other pandemic-related disruptions hit some Americans much harder than others. And it's been well documented that the death rate for Black Americans was twice as high compared with white Americans.

The disparity is reflected in the new longevity estimates. "African Americans saw their life expectancy decrease by 3.3 years and Hispanic Americans saw their life expectancy decrease by 3.9 years," Woolf noted.

"These are massive numbers," Woolf said, that reflect the systemic inequalities that long predate the pandemic.

"It is impossible to look at these findings and not see a reflection of the systemic racism in the U.S.," Lesley Curtis, chair of the Department of Population Health Sciences at Duke University School of Medicine, told NPR.

"This study further destroys the myth that the United States is the healthiest place in the world to live," Dr. Richard Besser, president of the Robert Wood Johnson Foundation (an NPR funder), said in an email.

He said wide differences in life expectancy rates were evident before COVID-19. "For example, life expectancy in Princeton, NJ—a predominantly White community—is 14 years higher than Trenton, NJ, a predominantly Black and Latino city only 14 miles away," Besser said.

Life expectancy in the U.S. had already been declining — albeit slowly — in the years leading up to the pandemic. And the U.S. has been losing ground compared with other wealthy countries, said Magali Barbieri of the University of California, Berkeley, in an editorial published alongside the new study.

The study estimates that the decline in life expectancy was .22 years (or about one-fifth of a year) in a group of 16 peer countries (including Austria, Finland, France, Israel, the Netherlands and the United Kingdom) compared with the nearly two-year decline in the United States.

"The U.S. disadvantage in mortality compared with other high income democracies in 2020 is neither new nor sudden," Barbieri wrote. It appears the pandemic has magnified existing vulnerabilities in U.S. society, she added.

"The range of factors that play into this include income inequality, the social safety net, as well as racial inequality and access to health care," Duke's Curtis said.

So, what's the prognosis going forward in the United States? "I think life expectancy will rebound," Woolf of Virginia Commonwealth said.

But it's unlikely that the U.S. is on course to reverse the trend entirely.

"The U.S. has some of the best hospitals and some of the greatest scientists. But other countries do far better in getting quality medical care to their population," Woolf said. "We have big gaps in getting care to people who need it most, when they need it most."

This content is from Southern California Public Radio. View the original story at SCPR.org.

Tents housing the homeless at an encampment in Echo Lake Park in Los Angeles, California on March 24, 2021.; Credit: FREDERIC J. BROWN/AFP via Getty Images

The Los Angeles City Council votes Thursday on a proposal to ban sleeping or camping in certain parts of the city, including near schools, parks, libraries, and other “sensitive” facilities like daycares. It would also ban tents and encampments from blocking sidewalks if wheelchair users cannot access them. The motion is a departure from the city’s previous approach to the homelessness crisis.

Council members voted 12 to 3 on Tuesday to pull the draft ordinance out of Homelessness and Poverty Committee, where it had been stuck since November, and directed City Attorney Mike Feuer’s office to draft the new rules. Today on AirTalk, we’re speaking with Los Angeles Times reporter Ben Oreskes about the proposed rules, what Thursday’s vote means, and what we know about possible legal ramifications of the proposed changes. 

Guest: 

Ben Oreskes, staff writer at the Los Angeles Times; he tweets @boreskes

This content is from Southern California Public Radio. View the original story at SCPR.org.

Sherman Institute, built in the Mission Revival architectural style, enrolled its first students on Sept. 9, 1902.; Credit: SHERMAN INDIAN MUSEUM

Earlier this month, Secretary of the Interior Deb Haaland announced an effort to search federal boarding schools for burial sites of Native American kids. 

The effort is similar to the one in Canada, which found the remains of up to 751 people, likely mostly children, at an unmarked grave in a defunct school in the province of Saskatchewan.  

We dive into the history of American Indian Boarding Schools, as well as their evolution and what the schools that still exist, including Sherman Institute High School in California, look like today.

Guests:

Brenda Child, professor of American Studies and American Indian Studies at the University of Minnesota; she is the author of many books, including “Boarding School Seasons: American Indian Families, 1900-1940” (University of Nebraska Press, 2000)

Amanda Wixon, curator at the Sherman Indian Museum, which is on the campus of Sherman Indian High School; assistant curator at Autry museum of the American West; PhD candidate in history at UC Riverside where her research is in Native American history, especially federal boarding schools and the carceral aspects of the Sherman Institute

This content is from Southern California Public Radio. View the original story at SCPR.org.

A homeless encampment is pictured at Venice Beach, on June 30, 2021 in Venice, California, where an initiative began this week offering people in homeless encampments a voluntary path to permanent housing.; Credit: FREDERIC J. BROWN/AFP via Getty Images

The majority of unhoused women across the nation — 57% according to recent data — say domestic violence is the direct cause of losing their permanent home. 

In L.A, almost 40% of women who are homeless say they’ve experienced abuse in the last 12 months.

The choice they’ve been forced to make: Stay in danger with their abusers — or escape, with nowhere to go.

“It’s like jumping from a burning building but there’s no net to catch you,” said Nikki Brown, a survivor and advocate.

There are many, complex reasons why survivors become homeless. Shame is one of them. Yet studies show that one in three women experience some form of intimate partner abuse in their lives. So why don’t we talk about it more?

“It's the greatest secret that's super common and nobody wants to admit it,” said Brown. “There are so many complicated circumstances that make it really hard to leave. And when you can't leave, that element of shame and blame is the thing that makes it so hard to talk about.”

Today on AirTalk, we’re learning more about reporter Julia Paskin’s series Pushed Out, on domestic violence and homelessness in Los Angeles. Do you have an experience you want to share? Give us a call at 866-893-5722.

Guests:

Julia Paskin, KPCC producer and reporter who created the “Pushed Out” series; she tweets @JuliaPaskinInc

Amy Turk, CEO of Downtown Women’s Center, which advocates and offers services for women experiencing homelessness and formerly homeless women; she tweets @AmyFTurk

Nikki Brown, staff attorney at Community Legal Aid SoCal, where she has clients that are domestic violence survivors

This content is from Southern California Public Radio. View the original story at SCPR.org.

The USGS is working with federal land management agencies to develop a series of structured science syntheses (SSS) to support National Environmental Policy Act (NEPA) analyses. This new synthesis is the third publication in the SSS series and provides science to support NEPA analyses for agency decisions regarding oil and gas leasing and permitting.

Emily shares her experience research on Henslow’s sparrow accounting for the future effects of climate change and to develop risk assessment tools to assist managers in the region with meeting their conservation objectives using prescribed fire.

Geologic mapping has been one of the most fundamental mandates of the U.S. Geological Survey (USGS) since its establishment in 1879. Congress created the USGS to "classify the public lands and examine the geological structure, mineral resources, and products within and outside the national domain."

These video talks, hosted by UAF Northwest Campus and Alaska Sea Grant, provide an overview of USGS Ecosystems research programs at the Alaska Science Center. These talks are designed to share information relevant to the community members of the Bering Strait Region.

At the tops of many mountains and along numerous roads across the USA are small brass disks called benchmarks.  These survey points are critical for mapping the landscape, determining boundaries, and documenting changes, and there are hundreds of them in Yellowstone National Park!

A voter marks his ballot at a polling place on Nov. 3, 2020, in Richland, Iowa. A new poll finds ensuring access to voting is more important than tamping down voter fraud for most Americans.; Credit: Mario Tama/Getty Images

A majority of Americans believes ensuring access to voting is more important than rooting out fraud, the latest NPR/PBS NewsHour/Marist survey finds.

At the same time, there was broad agreement that people should have to show identification when they go to the polls.

Two-thirds of Americans also believe democracy is "under threat," but likely for very different reasons.

"For Democrats, Jan. 6 undoubtedly looms large," said Lee Miringoff, director of the Marist Institute for Public Opinion, referring to the violence and insurrection at the Capitol, "while, for Republicans, it's more likely about Trump and his claims of a rigged election."

Voting access vs. fraud

By a 56%-41% margin, survey respondents said making sure that everyone who wants to vote can do so is a bigger concern than making sure that no one who is ineligible votes.

But there were wide differences by political party and by race.

Among Democrats, almost 9 in 10 said access was more important, but almost three-quarters of Republicans said it was making sure no one votes who isn't eligible.

By race, a slim majority of whites said ensuring everyone who wants to vote can was most important, but almost two-thirds of nonwhites said so.

Photo ID is popular

Nearly 8 in 10 Americans said they believe voters should be required to show government-issued photo identification whenever they vote.

Majorities of Democrats, Republicans, independents, whites and nonwhites all said so. Democrats were far lower, though, with 57% believing photo ID should be required.

Biden holding steady

President Biden gets a 50% job approval rating, largely unchanged from last month. There is a sharp partisan divide with 9 in 10 Democrats approving, and more than 8 in 10 Republicans disapproving.

Biden continues to get his highest ratings when it comes to his handling of the coronavirus pandemic, and his economic approval is holding steady. But Americans have less confidence in his handling of foreign policy, especially immigration. His approval on immigration ticked up slightly from March when it was last measured in the poll.

By a 50%-43% margin, respondents said Biden had strengthened America's role on the world stage.

Americans are split about whether the country is headed in the right direction or not — 49% said it wasn't, 47% said it was. It's an improvement, however, from right after the Jan. 6 insurrection when three-quarters said the country was on the wrong track.

The tone has gotten worse in Washington since Biden was elected, 41% said, but that's better than the two-thirds who said so consistently during the Trump years.

Methodology: The poll of 1,115 U.S. adults was conducted using live telephone interviewers from June 22-29. Survey questions were available in English or Spanish. The full sample has a margin of error of plus or minus 3.7 percentage points with larger margins of error for smaller group subsets.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Questlove attends Questlove's "Summer Of Soul" screening & live concert at Marcus Garvey Park in Harlem on June 19, 2021 in New York City.; Credit: Roy Rochlin/Getty Images

The 1960s was a decade that held a lot of historical markers for American history. For the Black community, social inequality and systemic racism lead to political action in many different forms.

The end of the decade saw the death of many integral leaders to the civil rights movement, which led to more civil unrest and mourning. One way this community was able to get through this moment in history was through the power of music. The 1969 Harlem Cultural Festival was a special moment in musical and Black history that was all a product of the other 8 years prior to it.

It’s a historical marker for Harlem that Ahmir “Questlove” Thompson’s film “Summer of Soul” depicts in-depth, bringing this story to life using archival footage and interviews. The Harlem Cultural Festival took place for 6 weeks, having some of the greatest Black musical acts the world has ever seen. Through this communal experience, attendees found themselves at ease with artists like Stevie Wonder, Nina Simone and the 5th Dimension bringing this community of Harlem residents together. 

Today on FilmWeek, Larry Mantle speaks with Ahmir “Questlove” Thompson about his feature directorial debut, “Summer of Soul (...Or, When the Revolution Could Not Be Televised),” and its chronicling of a major point in African American history.

Guest:

Ahmir “Questlove” Thompson, director of the documentary “Summer of Soul (...Or, When the Revolution Could Not Be Televised),” drummer for The Roots and The Tonight Show with Jimmy Fallon; he tweets @questlove

This content is from Southern California Public Radio. View the original story at SCPR.org.

Michael Ballanger of GGM Advisory Inc. shares his thoughts on the silver market and shares one copper stock he believes is a Strong Speculative Buy even though the stock is currently halted.

Full Text:

Earth's magnetic field seems steady and true -- reliable enough to navigate by. Yet, largely hidden from daily life, the field drifts, waxes and wanes. The magnetic North Pole is currently shifting toward Siberia, forcing the Global Positioning System that underlies modern navigation to update its software sooner than expected. Every several hundred thousand years, the magnetic field dramatically shifts and reverses its polarity. Magnetic north flips to the geographic South Pole and, eventually, back again. This reversal has happened countless times over Earth's history, but scientists' understanding of why and how the field reverses is limited. The researchers find that the most recent field reversal 770,000 years ago took at least 22,000 years to complete, several times longer than previously thought. The results call into question controversial findings that some reversals could occur within a human lifetime.

Image credit: Brad Singer

Full Text:

A National Science Foundation-funded study found that Charles Darwin's famous finches defy what has long been considered a key to evolutionary success: genetic diversity. The research on finches of the Galapagos Islands could change the way conservation biologists think about a species' potential for extinction in naturally fragmented populations. Researchers examined 212 tissue samples from museum specimens and living birds. Some of the museum specimens in the study were collected by Darwin himself in 1835. Only one of the extinct populations, a species called the vegetarian finch, had lower genetic diversity compared to modern survivors. Specifically, researchers believe a biological phenomenon called sink-source dynamics is at play in which larger populations of birds from other islands act as a "source" of immigrants to the island population that is naturally shrinking, the "sink." Without these immigrant individuals, the natural population on the island likely would continue to dwindle to local extinction. The immigrants have diverse genetics because they are coming from a variety of healthier islands, giving this struggling "sink" population inflated genetic diversity.

Image credit: Jose Barreiro

Full Text:

A new study shows that the West Antarctic Peninsula is experiencing some of the most rapid climate change on Earth, featuring dramatic increases in temperatures, retreats in glaciers and declines in sea ice. The Southern Ocean absorbs nearly half of the carbon dioxide -- the key greenhouse gas linked to climate change -- that is absorbed by all the world's oceans. The study tapped an unprecedented 25 years of oceanographic measurements in the Southern Ocean and highlights the need for more monitoring in the region. The research revealed that carbon dioxide absorption by surface waters off the West Antarctic Peninsula is linked to the stability of the upper ocean, along with the amount and type of algae present. A stable upper ocean provides algae with ideal growing conditions. During photosynthesis, algae remove carbon dioxide from the surface ocean, which in turn draws carbon dioxide out of the atmosphere. From 1993 to 2017, changes in sea ice dynamics off the West Antarctic Peninsula stabilized the upper ocean, resulting in greater algal concentrations and a shift in the mix of algal species. That's led to a nearly five-fold increase in carbon dioxide absorption during the summertime. The research also found a strong north-south difference in the trend of carbon dioxide absorption. The southern portion of the peninsula, which to date has been less impacted by climate change, experienced the most dramatic increase in carbon dioxide absorption, demonstrating the poleward progression of climate change in the region.

Image credit: Drew Spacht/The Ohio State University

Source: Dr. Robert Driscoll 10/28/2024

Wedbush analysts Dr. Robert Driscoll, Dr. Ritika Das, and Sam Ravina, in a research report published on October 28, 2024, maintained their Outperform rating on Monte Rosa Therapeutics Inc. (GLUE:NASDAQ) while raising their price target to US$15.00 from US$11.00. The report follows Monte Rosa's announcement of a collaborative agreement with Novartis for the development of MRT-6160, its VAV1-degrader program.

The analysts highlighted the significant financial terms of the agreement, stating, "GLUE will receive an upfront payment of US$150M as well as total milestone payments of up to US$2.1B that will include US$1.5B in potential development and regulatory milestones that begin upon Ph 2 studies."

Regarding the partnership structure, the analysts noted, "Upon start of Ph 3 studies, 30% US P&L would be shared with Ph 3 development co-fund and ex-US tiered royalties. Importantly, NVS will cover the complete costs of Ph 2 studies and will obtain worldwide rights to develop, commercialize and manufacture MRT-6160 as well as other VAV MGDs."

The analysts viewed this collaboration positively, stating, "We view this favorable collaboration agreement as an additional robust validation of GLUE's QuEEN MGD platform (noting Novartis' significant efforts in the degrader space), as well as an acknowledgment of the significant potential opportunities around targeting VAV1 with a first in class degrader."

They also emphasized the strategic benefits, noting, "Furthermore, we note the likely accelerated timelines for the MRT-6160 development program overall, and significant extension of GLUE's operational cash runway, which we expect to allow advancement of its deep pipeline."

The report highlighted the ongoing Phase 1 SAD/MAD healthy subject study for MRT-6160 in autoimmune diseases, with initial data expected in 1Q:25.

Wedbush's valuation methodology is based on sales multiples. The analysts explained, "Our PT is derived from applying a 6x multiple to estimated US sales and a 15x multiple to EU royalties of MRT-2359 in 2031, discounted by 30% annually."

The analysts also outlined several risk factors, including potential clinical and regulatory failure of MRT-2359, challenges in achieving sales estimates, and possible commercial competition from current and future therapies.

In conclusion, Wedbush's increased price target to US$15 reflects growing confidence in Monte Rosa Therapeutics following the Novartis collaboration agreement. The share price at the time of the report of US$8.05 represents a potential return of approximately 86% to the analysts' target price, highlighting the significant upside potential as the company advances its development programs with its new partner.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
2. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for Wedbush, Monte Rosa Therapeutics Inc., October 28, 2024

Analyst Certification We, Robert Driscoll, Ritika Das and Sam Ravina, certify that the views expressed in this report accurately reflect our personal opinions and that we have not and will not, directly or indirectly, receive compensation or other payments in connection with our specific recommendations or views contained in this report.

The Distribution of Ratings is required by FINRA rules; however, WS' stock ratings of Outperform, Neutral, and Underperform most closely conform to Buy, Hold, and Sell, respectively. Please note, however, the definitions are not the same as WS' stock ratings are on a relative basis. The analysts responsible for preparing research reports do not receive compensation based on specific investment banking activity. The analysts receive compensation that is based upon various factors including WS' total revenues, a portion of which are generated by WS' investment banking activities. Company Specific Disclosures This information is subject to change at any time. 2. WS managed a public offering of securities for Monte Rosa Therapeutics within the last 12 months. 4. WS has received compensation for investment banking services from Monte Rosa Therapeutics within the last 12 months. 5. WS provided Monte Rosa Therapeutics with investment banking services within the last 12 months.

Wedbush disclosure price charts are updated within the first fifteen days of each new calendar quarter per FINRA regulations. Price charts for companies initiated upon in the current quarter, and rating and target price changes occurring in the current quarter, will not be displayed until the following quarter. Additional information on recommended securities is available on request. Disclosure information regarding historical ratings and price targets is available: Research Disclosures *WS changed its rating system from (Strong Buy/ Buy/ Hold/ Sell) to (Outperform/ Neutral/ Underperform) on July 14, 2009. Applicable disclosure information is also available upon request by contacting the Research Department at (212) 833-1375, by email to leslie.lippai@wedbush.com. You may also submit a written request to the following: Wedbush Securities, Attn: Research Department, 142 W 57th Street, New York, NY 10019.

OTHER DISCLOSURES The information herein is based on sources that we consider reliable, but its accuracy is not guaranteed. The information contained herein is not a representation by this corporation, nor is any recommendation made herein based on any privileged information. This information is not intended to be nor should it be relied upon as a complete record or analysis: neither is it an offer nor a solicitation of an offer to sell or buy any security mentioned herein. This firm, Wedbush Securities, its officers, employees, and members of their families, or any one or more of them, and its discretionary and advisory accounts, may have a position in any security discussed herein or in related securities and may make, from time to time, purchases or sales thereof in the open market or otherwise. The information and expressions of opinion contained herein are subject to change without further notice. The herein mentioned securities may be sold to or bought from customers on a principal basis by this firm. Additional information with respect to the information contained herein may be obtained upon request. Wedbush Securities does and seeks to do business with companies covered in its research reports. Thus, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see pages 3–7 of this report for analyst certification and important disclosure information. Retail Investors The information provided is for general informational purposes only and should not be considered an individual recommendation or personalized investment advice. The companies/investments mentioned may not be suitable for everyone. Each investor needs to review their own respective situation(s) before making any investment decisions. All expressions of opinion are subject to change without notice due to shifting market(s), economic or political conditions. Investment involves risks including the risk of principal. Past performance is no guarantee of future results and the opinions presented cannot be viewed as an indicator of future performance.

( Companies Mentioned: GLUE:NASDAQ, )

Source: Dr. David Nierengarten 11/07/2024

TScan Therapeutics Inc. (TCRX:NASDAQ) Phase 1 ALLOHA study, evaluating its lead therapeutic candidates TSC-100 and TSC-101 in hematologic malignancies, showed patients continuing to have a positive response after one year, reported Wedbush analyst Dr. David Nierengarten in a Nov. 5 research note. TSC-100 and TSC-101 are T-cell receptor-engineered T-cell therapies (TCR-Ts).

"We see a catalyst-rich next few months ahead with data building in prominence on stock impact," Nierengarten wrote.

87% Return Potential

Wedbush has a US$10 per share target price on the Massachusetts-based biotech, trading at the time of the report at about US$5.36 per share, noted the analyst. The difference between these figures implies an 87% return potential for investors.

TScan Therapeutics remains rated Outperform.

Durability of Response Data

Nierengarten presented the clinical trial's latest results. As of the July 8, 2024 data cutoff date, in Phase 1 of ALLOHA, 16 patients with hematologic tumors had been administered TSC-100 or TSC-101, and 11 patients had been given a placebo. Median follow-ups had occurred at 5.8 months and 5.3 months, respectively.

At the time, none of the patients in the treatment arm had had a relapse. In the control arm, however, three, or 27% of, the 11 patients had, and the median time to relapse was 159 days. The analyst explained that this is typical for patients receiving a hematopoietic stem cell transplant after reduced-intensity conditioning.

One year out from treatment, five patients were evaluable, and all remained relapse free and minimal residual disease negative at the time. These data underscore the durability of response to this TCR-T treatment, Nierengarten commented. Its safety profile was shown to be favorable still, with no patients experiencing dose-limiting toxicities or adverse events associated with allogeneic hematopoietic cell transplantation.

"Enrollment continues in dose expansion cohorts, and results could support a registrational trial as early as 2025, pending regulatory feedback," Nierengarten wrote.

On the Horizon

TScan Therapeutics has several catalysts related to its clinical programs on the horizon, which Nierengarten listed.

On Nov. 8 and 9, the company will present preclinical data in the poster sessions at the annual Society for Immunotherapy of Cancer meeting. One poster will show in vitro combinatorial data for T-Plex, TScan's cellular therapy for treating solid tumors. It is comprised of two to three different TCR-Ts that target different tumor antigens on different human leukocyte antigen (HLA) types.

A second poster will detail the expansion of ImmunoBank, the biotech's diverse bank of therapeutic T-cell receptors (TCRs) that recognize diverse targets and are associated with multiple HLA types. The third will depict development of a target agnostic platform to evaluate how TCR-Ts affect primary human tissues.

On Dec. 9, TScan Therapeutics will present updated one-year data from ALLOHA, at the American Society for Hematology Annual Meeting in December.

By year-end, the biotech will announce initial data from administering singleplex therapy, cell therapy engineered using a single TCR, to patients with solid tumors. This treatment is being given to establish safety before administering multiplex therapy, cell therapy engineered from multiple TCRs.

In 2025, TScan Therapeutics will provide long-term duration of response data for multiplex therapy in solid tumors and will potentially commence a registrational trial for TSC-100 and TSC-101.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
2. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for Wedbush, TScan Therapeutics Inc., November 5, 2024

Analyst Certification We, David Nierengarten, Martin Fan and Dennis Pak, certify that the views expressed in this report accurately reflect our personal opinions and that we have not and will not, directly or indirectly, receive compensation or other payments in connection with our specific recommendations or views contained in this report.

Company Specific Disclosures This information is subject to change at any time. 1. WS makes a market in the securities of TScan Therapeutics, Inc.. 6. WS is acting as a financial advisor for TScan Therapeutics, Inc..

Wedbush disclosure price charts are updated within the first fifteen days of each new calendar quarter per FINRA regulations. Price charts for companies initiated upon in the current quarter, and rating and target price changes occurring in the current quarter, will not be displayed until the following quarter. Additional information on recommended securities is available on request. Disclosure information regarding historical ratings and price targets is available: Research Disclosures *WS changed its rating system from (Strong Buy/ Buy/ Hold/ Sell) to (Outperform/ Neutral/ Underperform) on July 14, 2009. Applicable disclosure information is also available upon request by contacting the Research Department at (212) 833-1375, by email to leslie.lippai@wedbush.com. You may also submit a written request to the following: Wedbush Securities, Attn: Research Department, 142 W 57th Street, New York, NY 10019.

OTHER DISCLOSURES The information herein is based on sources that we consider reliable, but its accuracy is not guaranteed. The information contained herein is not a representation by this corporation, nor is any recommendation made herein based on any privileged information. This information is not intended to be nor should it be relied upon as a complete record or analysis: neither is it an offer nor a solicitation of an offer to sell or buy any security mentioned herein. This firm, Wedbush Securities, its officers, employees, and members of their families, or any one or more of them, and its discretionary and advisory accounts, may have a position in any security discussed herein or in related securities and may make, from time to time, purchases or sales thereof in the open market or otherwise. The information and expressions of opinion contained herein are subject to change without further notice. The herein mentioned securities may be sold to or bought from customers on a principal basis by this firm. Additional information with respect to the information contained herein may be obtained upon request. Wedbush Securities does and seeks to do business with companies covered in its research reports. Thus, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see pages 3–7 of this report for analyst certification and important disclosure information. Retail Investors The information provided is for general informational purposes only and should not be considered an individual recommendation or personalized investment advice. The companies/investments mentioned may not be suitable for everyone. Each investor needs to review their own respective situation(s) before making any investment decisions. All expressions of opinion are subject to change without notice due to shifting market(s), economic or political conditions. Investment involves risks including the risk of principal. Past performance is no guarantee of future results and the opinions presented cannot be viewed as an indicator of future performance.

( Companies Mentioned: TCRX:NASDAQ, )

Source: Streetwise Reports 11/08/2024

Vertex Pharmaceuticals Inc. (VRTX:NASDAQ) has reported a robust financial performance for the third quarter of 2024. The report has demonstrated the company's continued revenue growth and the strengthening of its innovative pipeline. For Q3 2024, Vertex's product revenue reached US$2.77 billion, a 12% increase from the previous year. This was primarily driven by strong demand for its TRIKAFTA®/KAFTRIO® therapies. Based on this momentum, Vertex raised its full-year product revenue guidance to a range of US$10.8 billion to US$10.9 billion, citing a solid trajectory in its cystic fibrosis (CF) portfolio and expected future launches.

In Q3, the company made notable advancements in its pipeline. Three programs have begun moving into Phase 3 clinical development: suzetrigine in diabetic peripheral neuropathy (DPN), povetacicept in IgA nephropathy (IgAN), and VX-880 in type 1 diabetes (T1D). Vertex is also preparing for the launch of two potential treatments in early 2025, with PDUFA dates set for January 2 for the vanzacaftor triple therapy for CF and January 30 for suzetrigine, the latter being a pain medication in a new therapeutic class aimed at reducing reliance on opioids.

GAAP and Non-GAAP net income both reached US$1.0 billion, largely driven by increased product revenue, which offset rising R&D and SG&A expense. This was s due to investments in global commercialization and late-stage clinical development. For Q3, Vertex's combined R&D and SG&A expenses were US$1.2 billion and US$1.1 billion, respectively, an increase from last year attributed to new global program advancements and upcoming launch support.

Vertex's cash position remained strong, with US$11.2 billion in cash, cash equivalents, and marketable securities as of September 30. The decline from US$13.7 billion at the end of 2023 primarily reflects the acquisition of Alpine Immune Sciences and share repurchases under the company's buyback program.

A Look At Biotechnology and Pharma

The U.S. Pharmaceuticals Report for 2024 by Nova One Advisor detailed the size and growth trajectory of the U.S. pharmaceutical market. Valued at US$602.19 billion in 2023, the sector is projected to exceed US$1 trillion by 2033. The report pointed to a "high healthcare expenditure provided by government bodies" as a primary growth driver, further bolstered by the aging population's demand for advanced treatments.

In an October 24 article, The Investing News Network reported on a dynamic landscape within the biotechnology sector. The report highlighted advancements in AI-powered drug discovery. Despite a cautious investment climate, interest remained strong in AI's potential to reshape healthcare, with venture capital investment reaching US$6.59 billion. At the HealthTech Ignite conference, Susie Roberts from Relay Therapeutics expressed confidence, noting, "We will definitely see AI design drugs in the next 10 years."

On November 4, Yahoo! Finance shared insights from MIT professors Andrew Lo and Dennis Whyte. They emphasized that biotechnology's rapid advancement over the past five decades offers valuable lessons for future innovation. In their research paper, Lo and Whyte proposed initiatives to accelerate biotechnology's growth, underscoring the importance of "reducing risk and uncertainty" to foster a robust investment ecosystem that supports groundbreaking discoveries.

Catalysts Driving Vertex Pharma

According to Vertex's November 2024 investor presentation, the company sees multiple growth catalysts over the next few years. Vertex aims to meet its goal of achieving "five launches in five years," focusing on expanding the treatable patient base in CF with vanzacaftor triple, addressing critical needs in sickle cell disease (SCD) and beta thalassemia (TDT) with CASGEVY, and launching suzetrigine for acute pain management.

Additionally, Vertex expects its expansive R&D pipeline to support long-term growth. This includes pivotal clinical trials for VX-880 in T1D, povetacicept in IgAN, and NaV1.8 pain inhibitors like suzetrigine, indicating a commitment to treating a range of chronic and life-threatening conditions with limited therapeutic options.

By driving advancements in CF therapies, diversifying its portfolio with novel pain treatments, and pursuing accelerated approvals for renal and blood-related disorders, Vertex is strategically positioning itself to sustain growth and achieve several near-term milestones.

What Are Experts Saying About Vertex?

In a November 5, 2024, H.C. Wainwright & Co. update, the analysts highlighted promising data from Vertex's recent Phase 2 trial for suzetrigine, which showed encouraging reductions in pain intensity. [OWNERSHIP_CHART-4085]

The analysts noted that suzetrigine's peripheral nervous system-specific mechanism could potentially address "a significant, unmet medical need worldwide" in non-opioid pain management. They set a price target of US$600.00, projecting Vertex's continued growth from its strong cystic fibrosis franchise and pipeline expansion.

From the November 7 Kingswood Capital Partners report, analysts noted Vertex Pharmaceuticals' "sustained execution" in advancing product development programs and achieving robust operating margins, enabling "continued, significant investments" in both its pipeline and commercial capabilities. The firm maintained a "Buy" rating with a 12-month target price of US$550.00, attributing this outlook to Vertex's deep cash resources and historical successes in clinical trials.

Ownership and Share Structure

According to Refinitiv, 95.44% of Vertex Pharmaceuticals is held by Institutions. The top among them are Capital World Investors at 10.37%, The Vanguard Group at 8.88%, BlackRock Institutional Trust with 5.49%, State Street Global Advisors (US) with 4.55%, and Fidelity Management and Research with 4.11%. Strategic Investors hold .12%. The rest is retail.

The company's market cap is US$129,395.59 million with 257.07 million free float shares. The 52 week range is US$341.90–$510.64.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1) James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.

2) This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

( Companies Mentioned: VRTX:NASDAQ, )

WHEN:Wednesday, October 21Time: 11am PT / 2pm ET Join Now!>> SPONSORED BY: Citrix Online Audio Services GroupJoin us for this FREE live webcast to hear Marc Beattie of Wainhouse Research as he...

On-Demand Webinar > Watch Now! SPONSORED BY: TripwireWatch this FREE on-demand webinar to learn how to overcome the top 5 compliance challenges keeping IT directors awake at night! Watch Now! Overc...

On-Demand Webcast>Watch Now! SPONSORED BY: TripwireWatch this FREE on-demand webcast and hear from leading IT experts about ways organizations are leveraging technologies such as virtualizatio...

On-Demand Webinar >   Watch Now!>>SPONSORED BY: Juniper NetworksWatch this FREE on-demand webinar to learn how you and your company can get started down the road to reach the pinnacle ...

This Canadian explorer plans to spend the capital on advancing the silver-copper-manganese project in Peru of which it is working toward 100% ownership. Find out why one expert rates the company Buy.

The growth of artificial intelligence, the need for more computer data centers, the eventual adoption of electric vehicles (EVs), and the need for more net-zero power means nuclear power, and the uranium needed to fuel it, is seeing a resurgence. Here are some options to make the situation work for your portfolio.

Skyharbour Resources Ltd. (SYH:TSX.V; SYHBF:OTCQX; SC1P:FSE) has completed its earn-in requirements for a 51% interest at the Russell Lake Uranium Project in the central core of Canada's Eastern Athabasca Basin in Saskatchewan. This comes as the need for more net-zero power is sparking a rebirth of the nuclear industry.

James Franco attends a special screening of the final season of "The Deuce" at Metrograph on Sept. 5, 2019 in New York City. =; Credit: Taylor Hill/WireImage/Getty Images

The parties involved in a sexual misconduct case against Oscar-winning actor James Franco have reached a preliminary settlement agreement. The two actors who filed the suit have agreed to drop their claims.

In 2019, Sarah Tither-Kaplan and Toni Gaal alleged that James Franco's Studio 4 acting school sexually exploited female students. The complaint, filed in Los Angeles Superior Court, also alleged fraud and sought to represent more than 100 former female students at the now defunct Studio 4. Vince Jolivette, Jay Davis and Franco's RabbitBandini Productions were also named in the suit which accused Studio 4 of setting out to "create a steady stream of young women to objectify and exploit."

According to their joint status report filed on Feb. 11, Tither-Kaplan and Gaal agreed to drop their individual claims. The Sexual Exploitation Class claims will also be dismissed. NPR is reaching out to both parties for comment.

The original complaint was filed shortly after Franco won a Golden Globe for his performance in The Disaster Artist. Franco denied the allegations. In a statement to NPR at the time, his attorney said "James will not only fully defend himself, but will also seek damages from the plaintiffs and their attorneys for filing this scurrilous publicity seeking lawsuit."

In 2016, Franco made a docuseries based on his Sex Scenes class at Studio 4 that he posted on his Facebook page. The videos have since been taken down, but one is still available on Vimeo. Tither-Kaplan, who was a student in the class, told NPR she thought it would teach her how to "maneuver in sex scenes professionally as an actor," but it "did not do that at all."

According to Tither-Kaplan, the class did not explain industry standards such as "nudity riders, the detail required in them, the right to counsel with the director about nude scenes, the custom to choreograph nude scenes ahead of time to negotiate them with the cast and the director — I knew none of that throughout that class."

According to the parties' agreement, the allegations of fraud will be "subject to limited release." It is not clear whether monetary payments are involved. The parties say they expect to file a motion for preliminary approval of the settlement agreement no later than March 15.

This content is from Southern California Public Radio. View the original story at SCPR.org.

The pandemic has once again felled Burning Man. Some burners still plan to gather for informal events on the dusty Black Rock Desert Playa this summer.; Credit: Bernard Friel/Education Images/Universal Images Group via Getty Images

And so it goes: Burning Man 2021 is canceled. It's the second year in a row, the popular arts festival won't be held in Nevada's Black Rock Desert due to the pandemic.

"We have decided to set our sights on Black Rock City 2022," event officials announced in a blog post on Tuesday. In a frequently-asked-questions section, organizers added: "We've heard from many who don't feel ready to come to Black Rock City. While we're confident in our ability to get a permit and to safeguard public health, we know that co-creating Black Rock City in 2021 would put tremendous strain on our community while we are still ironing out uncertainty."

Many would-be attendees praised the decision in comments on the Burning Man website and on social media as a safe one; others are anxiously anticipating a bigger and better 2022 Burn.

But the cancellation has put many people in the event's host community at ease.

Wary of a trend of rising coronavirus cases in some parts of the region, Washoe County's district health officer Kevin Dick said "the right call was made," in order to lower the risk of spreading infection.

"The event draws thousands of people from all over the world," Dick said in an email. "We are seeing large outbreaks of COVID-19 occurring in a number of countries, areas where very contagious COVID-19 variants of concern are prevalent and where low rates of vaccination are occurring."

The head of a local Paiute tribe is also feeling less burdened knowing there won't be the annual pilgrimage. The main highway to get to the Black Rock Desert playa, which normally draws tens of thousands of people to the summer event, cuts through tribal lands.

"For us it is a sigh of relief," said Janet Davis, chairwoman of the Pyramid Lake Paiute Tribe.

Although the event — which brings in about $63 million to the state annually — gives the tribal community a welcome financial boost, Davis said.

"We don't know who's vaccinated and who's not," she said. "We've been trying to keep our reservation safe and that happening was too soon for us to open."

As with last year, the organization will offer virtual programming during Burn Week, from Aug. 29 through Sept. 7, an experience they say drew 165,000 participants in 2020.

In response to a request for more details on the reasons for the cancellation, Burning Man organizers declined to comment further. Earlier this month, though, CEO Marian Goodell said the organization was "weighing the gravity" of implementing a vaccination requirement that she said challenged "radical inclusion," one of the group's 10 principles.

Still, for many burners, the news won't extinguish their plans to trek to the desert in droves. Just like last year, revelers are preparing to hold unofficial gatherings on public land in place of the annual event.

Last summer, those events — the so-called "rogue" and "free" burns or, unmistakably, "Not Burning Man" — drew an estimated 3,000 people to Black Rock Desert during the time Burning Man is normally held, according to the Bureau of Land Management, the federal agency that approves the organization's permits each year.

Kevin Jervis, one such attendee who now lives in Gerlach — a tiny desert town near the event site — welcomed this year's cancellation.

He called it "more of a relief than anything. ... A lot of us liked it better the way it happened last year."

During the informal festivities, Jervis spent a few days between the playa and its outskirts. He said he and his fellow burners felt like it represented the festival's freewheeling roots.

"I've had friends that have been going since '94 and they said it was a lot more like it used to be. We didn't have to go by regulations," he said. "We could have guns, dogs ... it was a lot freer."

Even before the pandemic, burners increasingly saw an annual gathering under siege.

Event-goers who adhere to Burning Man's counterculture beginnings say the festival's explosion in popularity in the past decade has welcomed a host of bad actors who trash the desert and surrounding communities and disregard the event's founding principles, including "decommodification" and the eco-friendly philosophy of "leave no trace."

Some of those perceived threats come from festival officials themselves, he said. A ticket to the main event alone cost over $400 in 2019 — a financial hurdle critics say goes against another tenet long espoused, that "everyone is invited."

"People that have never been before came out last year because they either couldn't get a ticket other years or they were just kind of curious. Or they didn't have the money to go to the actual Burn," said Jervis.

As for the Pyramid Lake Paiute community, with the reservation largely closed during that period last year, Davis said, "we really didn't see the impact" from a public health standpoint.

"You're not talking about 65 — 75,000 people." While there was more traffic, she said, "they moseyed on through and moseyed on out."

In the years leading up to the pandemic, BLM had been cracking down on the event's growth. Were the festival to return this year, Burning Man organizers said they would have had to meet a population cap of 69,000, down from its 80,000 limit for previous events.

Jervis says he won't miss what he describes as organizers' leniency toward "elites" who set up VIP areas at their camps and hire out to construct their art creations instead of making their own.

"A lot of people have gotten sick of what Burning Man's kind of become," he said.

Even if this year was a go, he said, burners would still be setting up their own Burning Man-adjacent happenings.

Following the announcement of the event's cancellation, people are taking to Facebook groups to reminisce about last year's unsanctioned burns and discuss preparations for their own this summer.

"So it seems that as of today there isn't going to be an official [Burning Man Ceremony] this year," James Zapata wrote. "So who's joining me in the dust?"

This content is from Southern California Public Radio. View the original story at SCPR.org.

Global Analyst Adrian Day reviews results from two high-quality companies, a gold miner and a global blue chip. He also looks at changes in gold trends.

Dryden Gold Corp. (DRY:TSXV; DRYGF:OTCQB) has announced its participation in three significant mining investment conferences scheduled for November 2024. Read more about the company's plans to showcase major project updates and connect with global investors at these key events.

The convergence of voice, video and data is old news today, but when it happened it changed the world.  New possibilities became available for the delivery of services like phone, movies and entertainment. All this was enhanced with the flood of small mobile devices.  And now, we love being able to use our smartphone to [...]

A photo of La Soufrière erupting Friday in St. Vincent. The blast could be sending ash as far as Jamaica and South America.; Credit: Zen Punnett/AFP via Getty Images

La Soufrière, the highest peak on the Caribbean island of St. Vincent, began to explosively erupt Friday morning, forcing thousands to evacuate as ash and smoke filled the sky.

And a larger eruption may be on the way.

Richard Robertson, a geologist with the University of the West Indies Seismic Research Centre, said the volcano is in its explosive eruption phase. The initial explosion of dust and debris St. Vincent experienced Friday is likely just the beginning.

"The explosive eruption has started and it is possible you could have more explosions like these," he said during a press conference. "The first one is not necessarily the worst one, the first bang is not necessarily the biggest bang this volcano will give."

Ralph Gonsalves, the prime minister of St. Vincent and the Grenadines, ordered residents on the northern side of the island to evacuate Thursday out of the red volcano danger zone. The Associated Press reported some 16,000 people were forced to flee their homes.

Soot and ash fell throughout the night, blanketing neighborhoods and streets across the island Saturday morning. Robertson said the ash is expected to fall for the next handful of days, possibly even weeks.

The dome of the volcano, which is about 3,100 feet long and more than 820 feet wide, was destroyed in Friday's eruption, catapulting 460 million cubic feet of debris into the atmosphere. The ash could reach as far as Jamaica and parts of South America, Robertson said.

The last time La Soufrière had a major eruption was in 1979, which lasted several weeks. This eruption, Robertson said, "will more than likely be a bigger eruption than 1979 was." He added, "We don't know how much material is down there that wants to come out."

The fine ash particles, which are difficult to clean up, pose a respiratory risk, especially for people with underlying issues. Robertson recommended that individuals who have decided to stay on the island do their best to clean the ash before it settles or gets wet.

With more potential eruptions looming, Robertson advised residents to move as far south as possible. La Soufrière could be heard rumbling and grumbling throughout the night, he said, from the sound of magma moving inside the volcano.

This content is from Southern California Public Radio. View the original story at SCPR.org.

SEOUL, South Korea (AP) — The United States and China, the world's two biggest carbon polluters, agreed to cooperate to curb climate change with urgency, just days before President Joe Biden hosts a virtual summit of world leaders to discuss the issue.

The agreement was reached by U.S. special envoy for climate John Kerry and his Chinese counterpart Xie Zhenhua during two days of talks in Shanghai last week, according to a joint statement.

The two countries "are committed to cooperating with each other and with other countries to tackle the climate crisis, which must be addressed with the seriousness and urgency that it demands," the statement said.

China is the world's biggest carbon emitter, followed by the United States. The two countries pump out nearly half of the fossil fuel fumes that are warming the planet's atmosphere. Their cooperation is key to a success of global efforts to curb climate change, but frayed ties over human rights, trade and China's territorial claims to Taiwan and the South China Sea have been threatening to undermine such efforts.

Meeting with reporters in Seoul on Sunday, Kerry said the language in the statement is "strong" and that the two countries agreed on "critical elements on where we have to go." But the former secretary of state said, "I learned in diplomacy that you don't put your back on the words, you put on actions. We all need to see what happens."

Noting that China is the world's biggest coal user, Kerry said he and Chinese officials had a lot of discussions on how to accelerate a global energy transition. "I have never shied away from expressing our views shared by many, many people that it is imperative to reduce coal, everywhere," he said.

Biden has invited 40 world leaders, including Chinese President Xi Jinping, to the April 22-23 summit. The U.S. and other countries are expected to announce more ambitious national targets for cutting carbon emissions ahead of or at the meeting, along with pledging financial help for climate efforts by less wealthy nations.

It's unclear how much Kerry's China visit would promote U.S.-China cooperation on climate issues.

While Kerry was still in Shanghai, Chinese Vice Foreign Minister Le Yucheng signaled Friday that China is unlikely to make any new pledges at next week's summit.

"For a big country with 1.4 billion people, these goals are not easily delivered," Le said during an interview with The Associated Press in Beijing. "Some countries are asking China to achieve the goals earlier. I am afraid this is not very realistic."

During a video meeting with German and French leaders Friday, Xi said that climate change "should not become a geopolitical chip, a target for attacking other countries or an excuse for trade barriers," the official Xinhua News Agency reported.

On whether Xi would join the summit, Le said "the Chinese side is actively studying the matter."

The joint statement said the two countries "look forward to" next week's summit. Kerry said Sunday that "we very much hope that (Xi) will take part" in the summit but it's up to China to make that decision.

Biden, who has said that fighting global warming is among his highest priorities, had the United States rejoin the historic 2015 Paris climate accord in the first hours of his presidency, undoing the U.S. withdrawal ordered by predecessor Donald Trump.

Major emitters of greenhouse gases are preparing for the next U.N. climate summit taking place in Glasgow, U.K., in November. The summit aims to relaunch global efforts to keep rising global temperatures to below 1.5 degrees Celsius (2.7 degrees Fahrenheit) as agreed in the Paris accord.

According to the U.S.-China statement, the two countries would enhance "their respective actions and cooperating in multilateral processes, including the United Nations Framework Convention on Climate Change and the Paris Agreement."

It said both countries also intend to develop their respective long-term strategies before the Glasgow conference and take "appropriate actions to maximize international investment and finance in support of" the energy transition in developing countries.

Xi announced last year that China would be carbon-neutral by 2060 and aims to reach a peak in its emissions by 2030. In March, China's Communist Party pledged to reduce carbon emissions per unit of economic output by 18% over the next five years, in line with its goal for the previous five-year period. But environmentalists say China needs to do more.

Biden has pledged the U.S. will switch to an emissions-free power sector within 14 years, and have an entirely emissions-free economy by 2050. Kerry is also pushing other nations to commit to carbon neutrality by then.

This content is from Southern California Public Radio. View the original story at SCPR.org.

The logo of National Oceanic and Atmospheric Administration is seen at the Nation Hurricane Center in Miami on Aug. 29, 2019. President Biden has nominated Rick Spinrad to head NOAA.; Credit: Eva Marie Uzcategui/Getty Images

President Biden is nominating Rick Spinrad to lead the National Oceanic and Atmospheric Administration, the government's premier agency on climate science which oversees the National Weather Service.

Prior to his current role as a professor of oceanography at Oregon State University, Spinrad served as NOAA's top scientist under President Obama and the U.S. representative to the United Nations' Intergovernmental Oceanographic Commission.

The nomination comes at a difficult moment in NOAA's history. The agency has been without an official, Senate-confirmed leader since former President Donald Trump took office in January 2017, after his two nominees to lead the agency failed to garner enough support to win a full vote before the Senate.

If Spinrad manages to win over the Senate, he will have to contend with a challenge beyond the agency's already-rigorous scientific mandate: restoring public confidence in a traditionally apolitical agency marred by political scandal.

In September 2019, then-President Trump wrongly said Alabama was in the projected path of Hurricane Dorian. He continued to reassert the claim for several days, including during an Oval Office briefing on the storm — in which he displayed what appeared to be an official National Weather Service map in which the storm's projected path was extended to Alabama by someone using a black marker.

After a National Weather Service office in Birmingham put out a tweet correctly stating that Alabama would not feel the effects of the storm, NOAA published an unsigned defense of the president's claims and rebuking its professional staff who posted the message.

Dan Sobien, then-president of the National Weather Service Employees Organization, said at the time that "the hard working employees of the NWS had nothing to do with the utterly disgusting and disingenuous tweet sent out by NOAA management."

If confirmed, Spinrad will lead a 12,000-person agency charged with a diverse portfolio that spans daily weather forecasts, climate monitoring, fisheries management and coastal restoration.

In a statement, the Environmental Defense Fund's Eric Schwaab applauded Spinrad's nomination, saying that NOAA's workers "couldn't ask for a better leader to restore scientific integrity and honor the agency's mission."

Biden, whose administration has made climate action a central focus, has proposed the largest budget in NOAA's history — $6.9 billion, a $1.5 billion increase over the 2021 budget allocated by Congress. It remains to be seen whether Congress will agree to the increase.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Florida Gov. Ron DeSantis speaks to the media about the cruise industry during a press conference at PortMiami in April. DeSantis faces criticism for failing to do all he could on Florida's biggest environmental threat: climate change.; Credit: Joe Raedle/Getty Images

Brick by brick, the stucco shell of a new flood-resilient public works building is taking shape blocks from the beach, the most visible sign yet of a small community's enormous task staving off the rising sea.

"This is actually the highest point in the city," Satellite Beach City Manager Courtney Barker said, adding that right next door to the new public works building will be a new fire station.

It's a close-knit community established by rocket scientists south of Kennedy Space Center, on a low-slung barrier island between the Atlantic Ocean and Indian River Lagoon.

By 2040, community leaders expect significant impacts associated with climate change. Already flooding is a problem, and beach-front homes perch precariously atop a sand dune left exposed after a series of storms and hurricanes washed away a sea wall.

The needs are great, and in Gov. Ron DeSantis, Barker sees a potential ally.

"At least he talks about climate change as actually being real, so that's good," she said. "And he's putting money toward it so that's encouraging."

But Barker also feels DeSantis is doing only part of the job.

"We desperately need to grow up as a state and realize that we need to get our emissions down," Barker said.

Since his election in November 2018, DeSantis is making good on some of his environmental promises, including what he likes to call "resilience," a new buzzword for climate adaptation. But as the governor prepares for a reelection bid in 2022, and is seen as a potential Republican frontrunner for the presidency in 2024, DeSantis faces criticism for failing to do all he could on Florida's biggest environmental threat: climate change.

Some of his critics acknowledge that the $1 billion Resilient Florida plan he announced in January could be a first step toward helping some communities pay for adaptation. But critics also point out that DeSantis has done almost nothing to put Florida on a path to scaling back the state's heavy reliance on fossil fuels.

"I would give him probably a C-minus," said former Republican Gov. Charlie Crist, who served from 2007 to 2011, and now represents St. Petersburg in the U.S. House of Representatives as a Democrat.

Crist still gets plaudits from environmentalists for his administration's climate initiatives, including a cap-and-trade system to curb carbon emissions and an executive order that was intended to put the state on a path to reducing its greenhouse gas emissions 80% by 2050. But those were basically abandoned by Gov. Rick Scott, the Republican now serving in the U.S. Senate.

Crist, who switched parties and this week announced he is running for governor in 2022, said DeSantis should be "encouraging renewables such as wind energy, solar energy, and particularly solar. I mean, my goodness, we're the Sunshine State."

DeSantis' press office declined to make the governor available for an interview and did not respond to written questions.

In comments at two press conferences earlier this year, the governor cited his support for spending hundreds of millions of dollars on water projects and Everglades restoration as evidence of his environmental credentials, while promising to double down on funding for coastal resilience.

Florida needs "to tackle the challenges posed by flooding, intensified storm events [and] sea level rise," he said. "When you look at how an insurance market would view property insurance, and to see that Florida is leading and trying to get ahead of some of these impacts, we think it'll be a very smart thing to do."

Lawmakers have had their own ideas on how to handle climate threats, and have passed two bills that, when taken together, are similar to DeSantis' Resilient Florida proposal.

"It's not exactly as he said he wanted it, but it's close," said Jonathan Webber, deputy director of Florida Conservation Voters. "These are policies that need to happen. It would have been better if they happened 20 years ago."

"I am not a global warming person"

In his 2018 campaign, DeSantis appealed directly to supporters of former President Donald Trump, such as in this ad where he tells one of his children to "build the wall" with toy blocks. The environment was a major issue in that election.

Residents were grappling with a toxic red tide and blue-green algae crisis that made beaches and waterways unsafe, and left marine-life belly-up.

In recent years Floridians have also experienced deadly, devastating consequences of back-to-back major hurricanes.

All the while, advocates were highlighting likely links between the state's environmental woes and global warming.

Florida's climate challenges are among the biggest in the country. Beyond those related to hurricanes intensified by climate change, they include sea level rise, extreme heat, drought and increasing health threats from mosquito-borne diseases.

By its own numbers, the DeSantis administration predicts that with sea level rise, $26 billion in residential property statewide will be at risk of chronic flooding by 2045.

But in 2018, DeSantis let voters know that he had clear limits when it came to climate change.

"I am not in the pews of the church of the global warming leftists," DeSantis told reporters at one 2018 campaign stop. "I am not a global warming person. I don't want that label on me."

Early plaudits from environmentalists

Once in office, DeSantis won early plaudits for directives aimed at cleaning up water and helping Florida adapt to climate change. He appointed the first state resilience officer and the first chief scientist, and ordered Florida's Department of Environmental Protection to make sure its decisions were based on the best available science.

In 2019, they approved of DeSantis' order to his environmental regulators to oppose fracking, but he since has failed to get his Republican colleagues in the legislature to pass a statewide fracking ban, something he advocated for during his campaign. The state's oil and gas industry does not currently use fracking as a drilling method, but environmentalists are worried it might start doing so, resulting in water pollution.

Environmental groups also praised DeSantis in 2020 when the governor announced the state was backing a plan to buy 20,000 acres of the Everglades to prevent oil development there.

And they did the same when DeSantis backed spending $166 million in settlement money Florida received from Volkswagen on electric vehicle charging stations and cleaner electric buses. The money, part of a larger $14.7 billion settlement, came after the German automaker was caught lying about its cars' diesel emissions.

"Everyone was optimistic," said Susan Glickman, the Florida director for the Southern Alliance for Clean Energy. "I kept hearing an opening on climate."

Two years later, though, Glickman and other advocates are assessing DeSantis' climate record much like this: He's done more than previous Governor Scott, but that's not saying much.

DeSantis quietly replaced his chief science officer in March with Mark Rains, a professor, and chair and director of the School of Geosciences at the University of South Florida. But he never has replaced his chief resilience officer after she left for the Trump administration after only a few months in the position.

"Missing in action" on renewables

In many ways, it's what DeSantis hasn't done that defines his climate record. He has chosen not to use his bully pulpit to advocate for a clean-energy future, like his Democratic Party counterparts in the Southeast states of North Carolina and Virginia, or like the mayors of Orlando and Tampa.

DeSantis has also been "missing in action" in debate over bills this year in the Florida legislature that would undermine local government efforts to transition to clean energy, said Webber, with the Florida Conservation Voters group.

One such bill, that has passed the House and Senate and awaits DeSantis' consideration, would ban local governments from restricting fuel sources. The oil and gas industry has supported such measures around the country. They aim to block the push by climate activists to ban natural gas hook-ups in new buildings, and electrify them instead to reduce carbon emissions.

Of course, electrification only reduces emissions if it's powered by renewable energy. But Florida has no requirement that utilities provide a certain amount of that. Solar power accounts for only about 2.5% of the electricity produced by utilities, while they rely on fossil fuels for about 84%.

When DeSantis had a chance to appoint someone to the state's powerful Florida Public Service Commission, a regulatory body with a big say in state energy policy, he chose the Florida chairman of the American Legislative Exchange Council, a group known for its support of fossil fuels.

"We are very frustrated by the messaging, and the lack of acknowledgement of the root of the problem of all these issues," said Yoca Arditi-Rocha, executive director of The CLEO Institute, a nonprofit that focuses on climate science education.

"We need to acknowledge the warming temperatures and the rising seas are a result of our warming climate," she said. "We cannot adapt our way out of it. We need to aggressively tackle mitigation."

"What places can we not save?"

In Satellite Beach, Courtney Barker, the city manager who welcomes the governor's help with adapting to climate change, also wants to see him tackle the emissions side of the equation.

Besides moving the public works building and fire station to higher ground, the community is fortifying its system of flood control. Barker said the community needs more funding opportunities from the state.

"We're looking for assistance in helping us engineer our way out of it," she said.

Marine and climate scientist Jeff Chanton, of Florida State University, thinks there's too much emphasis on sea walls, which can cause beach erosion and destroy tidal zones vital to marine life, including crabs and turtles.

"An ideal governor would try to lessen the impacts of growth in this state, especially along our coastlines," he said.

Before her departure, Julia Nesheiwat, DeSantis' chief resilience officer, characterized the state's infrastructure as "outdated" in a report, and called its resilience strategy "disjointed."

For Thomas Ruppert, an attorney and coastal planning specialist with Florida Sea Grant, DeSantis' emphasis on hardening infrastructure ignores that — for some communities — the investments will be futile in staving off the inevitable.

"Ultimately, what we really need is to start talking seriously [about] what places can we not save? And what is an exit strategy? Because we have no idea," Ruppert said.

Barker hopes it doesn't come to that in Satellite Beach, where she grew up.

"It's personal to all of us, because I think everyone can look at their own hometown, and you can't imagine being anywhere else."

This story is a collaboration between Inside Climate News and WMFE Orlando, a member of ICN's National Reporting Network-Southeast.

This content is from Southern California Public Radio. View the original story at SCPR.org.

When a promising new drug to treat obesity was approved by the Food and Drug Administration for sale in the U.S. last month, it was the first such treatment to gain approval since 2014.

In clinical trials, weekly injections of semaglutide — or Wegovy, as it's been branded -- helped people drop an average of 15% of their body weight. That's an average of about 34 pounds over 16 months, before their weight plateaued, a far greater weight loss, obesity specialists say, than achieved with other drugs on the market. At least as important, Wegovy raised none of the alarm bells with the FDA or obesity doctors that it might trigger serious side effects of the sort experienced by some people taking fen-phen or some previous medical treatments for obesity.

But with a price tag for Wegovy of $1,000 to $1,500 a month, a very big question remains: Will insurers cover its significant cost for the many millions of people like Marleen Greenleaf, who might benefit?

Greenleaf grew up on the island of Trinidad, where her entire family paid little heed to what they ate and paid a high medical price, she says: "My husband has diabetes, my sister has diabetes, my brother has diabetes."

Since then, she's tried — and failed — at numerous diets, says Greenleaf, now 58 and an administrator at a charter school in Washington, D.C. Then, in 2018, she signed up for the clinical trial of a new drug — a once-weekly shot that changes the way her brain signals hunger.

A drug that finally stops her cravings

She noticed the change soon after her first injection of Wegovy: "For me, there was something that triggered in my brain to tell me that I was not hungry," she says. No more fierce cravings for the chocolate chip cookies she adores. Without the cravings she was able to slow down and reconsider the foods she'd been reaching for.

"I also wanted to eat healthier," she says. "I was looking at options, reading labels, looking at the calories — not just the calories, but also the sugar."

Over the 68-week research trial, Greenleaf dropped 40 pounds. Her blood pressure fell, which meant she qualified to donate her kidney to her husband, who was on dialysis.

"It was one of the best gifts of life that I could have ever given," she says.

But after that study ended, Greenleaf regained some of the weight. Wegovy is considered a long-term, possibly lifelong medication to treat chronic obesity. In the pre-marketing clinical studies, weight loss topped out at a total average weight loss of 15-18%, even as people continued to take the drug. And, as was the case with Greenleaf, once they stopped getting the weekly injections some of that weight came back.

Now, Greenleaf wants to resume the Wegovy shots.

"My only challenge actually is getting the insurance company to approve it," she says.

Reimbursement for obesity drugs' cost is patchy

Insurance coverage, it turns out, is a giant question — not just with Wegovy, but with obesity drugs in general. Some private insurers do include some prescription obesity drugs in the list of medicines they'll cover; it's too early to tell whether Wegovy will make those lists. Many doctors and patients are optimistic, because it is a higher dose of an existing diabetes medication called Ozempic, which is often covered by insurers.

A few select state Medicaid programs will cover medications that treat obesity, in some circumstances. But, significantly, Medicare does not cover obesity drugs — and many private insurers typically follow Medicare's lead.

Yet the demand for a good treatment is there, says Dr. Fatima Cody Stanford, a leading obesity researcher at Harvard. She was not involved in conducting the Wegovy clinical trial, but closely followed it. "I'm excited about it," she says, because of the dramatic weight loss.

The drug acts on the brain so people eat less and store less of what they eat. That helps address the excess weight as well as helping with numerous related diseases of the liver or heart, for example.

Why the FDA has been slow to approve obesity treatments

There is a long history of drugs that have looked like promising treatments for obesity, then failed. Decades ago, amphetamines, were prescribed, until their addictive properties became apparent. In the 1990s, the combination of fenfluramine and phentermine — administered as the diet drug fen-phen — was heavily marketed, only to later be pulled from the market for causing heart valve problems.

Those experiences and others have made physicians skeptical.

"In obesity medicine field, we've learned to be cautiously optimistic each time we have a new medication that looks promising," says Dr. Ihuoma Eneli, director of the Center for Healthy Weight and Nutrition at Nationwide Children's Hospital in Columbus, Ohio, who was not involved in the study of Wegovy.

So far, Eneli does not see any obvious concerns with the class of drugs that includes Wegovy, and calls the results so far "very promising." Wegovy is similar to another drug made by Novo Nordisk — Saxenda — which has been on the market since 2014, and which Eneli occasionally prescribes to her pediatric patients who are struggling with obesity.

In clinical research studies, the primary side effects reported after taking Wegovy affected the digestive system: nausea, diarrhea, vomiting, constipation, abdominal pain or intestinal infections.

Eneli says such side effects and their frequency are milder than the problems that have arisen in the past. That good safety profile may mean the drug is "less likely to come up with unanticipated risks," she says.

But, the new drug will be of little use, she and other doctors who treat obesity say, if it's not also affordable for patients.

"Before I even bring up that drug with my patients, I'm looking to see which insurance they are having on the left side of my screen — because that will determine whether I bring it up," Stanford, the Harvard physician, says. "If it's out of reach, like I said, I won't bring it up."

Stanford says her patients on existing obesity medications do extraordinary things to keep their coverage so they can afford to stay on the drugs.

"Several nurses here at the hospital that are my patients stayed working — they were supposed to retire — so they could stay on their injectable medication," Stanford says,"because that's how beneficial it was to them."

Why some are willing to pay out of pocket

Some people, like David Scheesley, 42, says he would consider paying for Wegovy, even if he had to pay the full sticker price. The Hanford, Calif., correctional officer has tried since 2019 to lose weight on various diets — low-fat, all-meat, all-vegetable — without success. His weight has led to other health concerns — with his blood fats and his heart — which makes Scheesley think of his 5-year-old son.

"I want to see him for a lot of years; I don't want to have a stroke," he says. "I don't want to have diabetes. I want to be there for him. So, for me personally, that [monetary cost] is not astronomical, if it can give me some more time."

Novo Nordisk, the company that makes Wegovy, is in talks with insurers, and acknowledges that ensuring health insurance coverage of its drug is critical. The challenge, says Douglas Langa, executive vice president of Novo Nordisk North America, is getting doctors, patients, and politicians to recognize obesity as a disease — and that therefore insurance should cover the cost of medicine to treat it.

"There's a medical component to [obesity] that needs to be recognized; this is a disease state like we should be treating any other disease state," Langa says. He says about 40% of private insurers cover Saxenda, the similar weight-loss medication the company makes.

Langa tells insurance companies this, making the case for why prescriptions for Wegovy should be covered. His company is also heavily lobbying Congress to pass legislation to allow Medicare to cover obesity medications. It makes sense from a financial perspective, he argues, because obesity is the root disease underlying so many other diseases.

"We do believe insurers understand that [untreated obesity] is a gateway into 60 other health conditions," Langa says. The need is hard to ignore, he adds. More than 100 million people in the U.S. alone struggle with obesity.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Author Ta-Nehisi Coates, seen here in 2019, will join the faculty of Howard University.; Credit: Mary Altaffer/AP

Less than a week after trustees at the University of North Carolina at Chapel Hill belatedly voted to grant tenure to New York Times reporter Nikole Hannah-Jones, Howard University announced Hannah-Jones will instead be joining its faculty.

Howard, the prestigious historically Black university in Washington, D.C., also announced it is hiring writer and Howard alumnus Ta-Nehisi Coates, author of Between the World and Me.

Their positions were funded by nearly $20 million in donations from the Knight Foundation, the John D. and Catherine T. MacArthur Foundation and the Ford Foundation, as well as an anonymous donor.

The funding establishes the Knight Chair in Race and Journalism, a tenured position to be held by Hannah-Jones.

Hannah-Jones, who won a Pulitzer Prize for her 1619 Project, will also establish the Center for Journalism and Democracy, which the university says will train aspiring journalists in "the investigative skills and historical and analytical expertise needed to cover the crisis our democracy is facing."

The news is a blow to UNC, which has had its reputation damaged by its handling of Hannah-Jones' appointment to an endowed professorship at its journalism school. For months, trustees declined to consider granting her tenure, a highly unusual move considering her tenure was backed by the relevant academic leaders.

Some of the opposition came from Walter Hussman, an Arkansas newspaper publisher and alumnus whose $25 million donation to the UNC's journalism school led to its being named for him.

As NPR's David Folkenflik reported, Hussman said "he was given pause by some prominent scholars' criticism that Hannah-Jones distorted the historical record in arguing that the protection of slavery was one of the Founding Fathers' primary motivations in seeking independence from the British."

Amid the turmoil, other Black faculty members at UNC said they were considering leaving the university, and students protested on behalf of Hannah-Jones.

The university's student body president Lamar Richard penned an open letter last month to the UNC community, saying the university is unprepared for the reckoning that's required, and "[u]ntil this rebirth occurs, Carolina is not deserving of your talents, aspirations, or successes."

Hannah-Jones had said she would not accept UNC's offer without tenure, which UNC's Trustees finally approved in a 9-4 vote.

But the messy and contentious process spoiled it for her.

"Look what it took to get tenure," Hannah-Jones said, noting that every other chair of the position dating to the 1980s had been granted tenure, and that all were white. Hannah-Jones received unanimous approval from the faculty during the tenure process.

"And so to be denied it, and to only have that vote occur on the last possible day, at the last possible moment, after threat of legal action, after weeks of protest, after it became a national scandal – it's just not something that I want anymore," she told CBS This Morning.

Hannah-Jones said she never wanted her hiring to become a public scandal — she was simply hoping to give back to her beloved alma mater. And instead, she said, it became "embarrassing" to be passed over for tenure. She said she was never told by UNC-Chapel Hill's chancellor, provost or trustees why her tenure was not taken up in November or January.

The veteran journalist reportedly had offers from a number of universities after the botched process at UNC. So how did she pick Howard?

She said one of her few regrets was not going to Howard as an undergraduate. And she traced her choice to join its faculty to her own story, beginning as a second-grader bused to a white school.

"I've spent my entire life proving that I belong in elite white spaces that were not built for Black people," she told CBS. "I decided I didn't want to do that anymore. That Black professionals should feel free, and actually perhaps an obligation, to go to our own institutions and bring our talents and resources to our own institutions and help to build them up as well."

She said she won her battle for fair treatment at UNC, "but it's not my job to heal the University of North Carolina. That's the job of the people in power who created this situation in the first place."

Hannah-Jones said she's trying to raise even more money for Howard, and that she's eager to join the faculty this summer.

"To be able to bring that type of resources to a university that always punches above its weight, I'm so excited," she said. "Something great came out of this."

This content is from Southern California Public Radio. View the original story at SCPR.org.

Sonata Software announced that its Unified Enterprise Mobility Platform, Halosys, has been enhanced with additional features that boost optimization and usability